This study is an open-label study with an extension.
The study consists of 2 periods: an open label treatment period (16 weeks) and an extension (beyond 16 weeks).
Participants will receive mosliciguat in the 16-week treatment period.
All participants who complete the 16-week treatment period may continue to participate in the extension period where all participants will receive mosliciguat.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants willing and able to provide informed consent
Participants on inhaled treprostinil
Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:
1. Idiopathic interstitial pneumonia (IIP)
2. Chronic hypersensitivity pneumonitis
3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
Ability to perform 6MWD ≥100 meters.
You may not be if
Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
Exacerbation of underlying lung disease within 28 days prior to randomization.
Initiation of pulmonary rehabilitation within 28 days prior to randomization.
Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.
Clareo Health | A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
